Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tu Fu Ling Tablets
- Development stage
- Phase 2
- Lead developer
- Guangzhou Baiyunshan Jingxiutang Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Tu Fu Ling Tablets (also known as Tu Fu Ling Total Glucosides Tablets) is a traditional Chinese medicine-derived botanical extract formulation developed by Guangzhou Baiyunshan Jingxiutang Pharmaceutical and evaluated in clinical trials by the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. The drug consists of total glucosides extracted from *Smilax glabra* Roxb. (Rhizoma Smilacis Glabrae), with astilbin as a major active constituent. It acts as a selective immunosuppressant, primarily targeting activated T lymphocytes to inhibit immune-mediated inflammatory responses. Tu Fu Ling Tablets have been evaluated in Phase II clinical trials in China for the treatment of rheumatoid arthritis.
- Other names
- Smilax glabra total glycosides tabletsTotal glucosides of Rhizoma Smilacis Glabrae tabletsTu Fu Ling Total Glucosides Tablets土茯苓总苷片土茯苓片
02
Targets
ALDH2 (Mitochondrial Aldehyde Dehydrogenase)CD44 (CD44 antigen)MMP9 (Matrix metalloproteinase-9)NFKB1 (NF-κB1)RORC (Retinoic acid receptor-related orphan receptor gamma)OAT1 (Organic anion transporter 1)GLUT9 (Glucose transporter type 9)
Beyond the preview
Go deeper on Tu Fu Ling Tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tu Fu Ling Tablets.